Wednesday, July 8, 2026

pharma · H Pylori Infection · H. Pylori Infection · PHAT

Phathom Pharmaceuticals

Phathom Pharmaceuticals is a pharma organization headquartered in Florham Park, USA. It trades on NYSE under ticker PHAT. Primary therapeutic focus areas include H Pylori Infection, H. Pylori Infection, Eosinophilic Esop

100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US HQ
2018 Founded
420 Employees
Public company Type
PHAT · NYSE Ticker
Company details
Status
Public
HQ
100 Campus Drive, Suite 102, Florham Park, New Jersey 07932, US
Founded
2018
Employees
420
Programs
11
Drugs
5
Patents
8
Clinical program

Vonoprazan

Phase 3 · small molecule · Non-Erosive Gastro-Esophageal Reflux Disease

Vonoprazan for Non-Erosive Gastro-Esophageal Reflux Disease is a Phase 3 program (small_molecule) at Phathom Pharmaceuticals with 2 ClinicalTrials.gov record(s).

← All Phathom Pharmaceuticals projects Phase 3 small molecule completed

Internal code NERD-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Phathom Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Non-Erosive Gastro-Esophageal Reflux Disease
Status
completed
Trials
2